Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

In contrast, Eli Lilly (NYSE: LLY) and Hims & Hers Health (NYSE: HIMS) both jumped on today's news. They rose 2.7% and 7%, ...

New York-based Jones just raised $10 million to expand its nicotine lozenge company in the stodgy, $3 billion smoking cessation market.

On Wednesday last week, The Wall Street Journal reported that Hims & Hers "will keep offering pharmacy-made, or compounded, versions of Ozempic and Wegovy tweaked to individual prescriptions." ...

Health care companies slid as traders retreated from high-risk issues. Shares of obesity-drug maker Novo Nordisk and Hims & Hers Health, the compounding pharmacy seeking to compete with the ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

SHOPPING: Give yourself the gift of improved sense of self with the once-a-day treatment that contains ingredients to support ...

Obesity remains a significant public health challenge in the UK, with over 26% of adults classified as obese and an additional 38% considered overweight. This epidemic not only impacts individual ...

Patients taking compounded weight loss drugs from online pharmacies share what it's like — and they couldn't go the ...